4DMedical is a global leader in respiratory and cardiopulmonary software imaging using advanced technology and AI. It offers non-invasive, regional and lobar quantitative lung function analysis to enhance diagnosis of conditions like unexplained dyspnea, asthma, COPD, cystic fibrosis, and ILD. The company also provides low-dose lung health screening with customized smoking cessation tools for physicians to support their patients.
View the entire 4DMedical portfolio.
Friday, May 16 5:00–8:00pm
Saturday, May 17 7:00am–6:00pm
True Innovation.
4DMedical poster presentations showcase current and upcoming groundbreaking innovations:
Sunday, May 18–Tuesday May 20
10:30am–3:30pm, Booth 1827
CT:VQ* converts standard (non-contrast) CT scans into high-quality ventilation and perfusion datasets, comparable to SPECT V/Q studies, without nuclear imaging or tracers. It fills a critical healthcare gap by using prevalent CT infrastructure, enhancing access, efficiency, and patient flow. CT:VQ supports major clinical needs, like pulmonary hypertension and lung cancer planning, promising a new standard in lung function assessment and broad adoption.
*CT:VQ is available for investigation-use only at this time
Speaker:
Prof. Andreas Fouras, CEO
“Advancements in IPF Diagnosis: Accelerating Accurate Detection with IQ-UIP™”
IQ-UIP™ by 4DMedical is FDA-cleared software utilizing Deep Convolutional Neural Networks to identify Usual Interstitial Pneumonia Patterns (UIP) on thoracic HRCT scans, associated with IPF. A critical lung disease, IPF is often misdiagnosed as COPD, with rates over 50%. Validated on 800+ scans, IQ-UIP achieved a 0.96 ROC-AUC, helping expedite ILD specialist referrals to improve patient outcomes.
Speaker:
Jonathan Chung, MD
“Disease Burden in an At-risk Population With Early COPD: An Analysis of the MAP Cohort”
Using parametric response mapping, this research highlights that early lung changes and symptoms can be present before COPD is officially diagnosed, underscoring the need for early identification and prevention efforts.
Authors:
University of Michigan: J Wang, L Xu, S Murray, C Galban, E Kazerooni, J Curtis, W Labaki, M Han
University of Massachusetts: F Martinez
4DMedical: C Hatt
“A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis”
This study shows that quantitative CT measures—such as increased reticular opacity and reduced lung volume—can reliably predict worse outcomes in patients with fibrotic interstitial lung disease, including higher risk of death or transplant. The new qCT-based classification (qctPPF) was more consistent and prognostically significant than traditional radiology assessments, pointing to a better way to identify and track disease progression.
Authors:
University of Michigan: J Wang, J Pugashetti, S Murray, N Mohan, N Nazemi, E Kang, E Kazerooni, K Flaherty, E Belloli, J Sheth, D O’Dwyer, M Han, J Oldham
University of Chicago: A Adegunsoye, C Lee, L Chelala, M Strek, J Chung
4DMedical: C Hatt
Poster 518
Product: LDAf (Lung Density Analysis)
9:15–11:15am
Room 3010/3012 – West Building, Level 3
Poster 519
Product: XV LVAS (Lung Ventilation Analysis)
9:15–11:15am
Room 3010/3012 – West Building, Level 3
Poster P606
Product: XV LVAS (Lung Ventilation Analysis)
“Visualizing Lung Ventilation Heterogeneity in Children With X-ray Velocimetry”
11:30am–1:15pm
Area E, Hall F, North Building, Exhibition Level
Poster P878
Product: LDAf (Lung Density Analysis)
11:30am–1:15pm
Area G, Hall F – North Building, Exhibition Level
Poster 218
Product: XV LVAS (Lung Ventilation Analysis)
“X-ray Velocimetry Predicts Pneumothorax Risk After Endobronchial Valve Procedure”
2:15–4:15pm
Room 207/208 – South Building, Level 2
Poster 220
Product: Non-Contrast CT:VQ
2:15–4:15pm
Room 207/208 – South Building, Level 2
Poster 224
Product: LDAi (Lung Density Analysis)
2:15–4:15pm
Room 207/208 – South Building, Level 2
Poster 303
Product: LDAf (Lung Density Analysis)
9:15–11:15am
Room 213/214 – South Building, Level 2
Poster 902
Product: LDAf (Lung Density Analysis)
“A Computational Imaging Method for Small Airways Disease Staging in COPD”
9:15–11:15am
Room 3009/3011 – West Building, Level 3
Poster P303
Product: XV LVAS (Lung Ventilation Analysis)
“Feasibility of Performing X-ray Velocimetry Imaging in Children”
2:15–4:15pm
Room 213/214 – South Building, Level 2
Poster 612
Product: CAC (Coronary Artery Calcification)
2:15–4:15pm
Room 2002/2004 – West Building, Level 2
Poster 614
Product: IQ-UIP (Early IPF Identification)
9:15–11:15am
Room 2002/2004 – West Building, Level 2
Poster P344
Product: Non-Contrast CT:VQ
“A Novel Non-invasive 3D Assessment of Ventilation and Perfusion Mismatch in Patients With COPD”
11:30am–1:15pm
Area C, Hall F – North Building, Exhibition Level
Poster P353
Product: XV LVAS (Lung Ventilation Analysis)
11:30am–1:15pm
Area C, Hall F – North Building, Exhibition Level
Poster 603
Product: XV LVAS (Lung Ventilation Analysis)
8:15–10:15am
Room 2002/2004 – West Building, Level 2
IQ-UIP™—A New Approach to UIP Identification for IPF Management
Recognized as an FDA “Breakthrough Device” advancing early detection and intervention, IQ-UIP is innovative software that uses deep learning to accurately classify Usual Interstitial Pneumonia (UIP) and predict patient survival. Its performance matches that of expert CT readers. IQ-UIP integrates with inspiratory CT scans to provide instant analysis, significantly improving the efficiency of UIP identification. FDA-cleared in 2024, IQ-UIP sets a new benchmark in pulmonary diagnostics.
As COPD continues to grow as a global health burden—predicted by the World Health Organization (WHO) to become the third leading cause of death by 2030—innovative AI-driven medical imaging technologies are rapidly advancing diagnosis, staging, and treatment. In a recent Radiology Today article, “Breathing Room,” writer Beth W. Orenstein explores how clinicians are increasingly relying on advanced CT imaging solutions that overcome the limitations of traditional lung function testing methods such as spirometry, which can be uncomfortable and challenging for patients, particularly elderly and those with impaired lung capacity.
CT Ventilation Imaging from 4DMedical Shown to Rival Gold Standard PET Scans
A new peer-reviewed study published in Respiratory Research confirms that 4DMedical’s CT Lung Ventilation Analysis Software (CT LVAS) provides results comparable to those of the gold standard PET method, as well as two additional research techniques for assessing regional lung function. The findings demonstrate a strong association and agreement between 4DMedical’s CT LVAS and PET-ventilation at the lobar level and comparable correlation at the voxel level. Utilizing routine non-contrast CT scans, CT LVAS generates detailed regional ventilation information. This highlights CT LVAS as a safe and contrast-free modality for functional lung imaging, making it an ideal tool for assessing lung function across a range of respiratory conditions.
Population Health Screening—Identifying and Re-engaging At-risk Patients
Emphysema and COPD are underdiagnosed in up to 50% of patients, and often not identified until advanced stages. For these patients, options like Bronchoscopic Lung Volume Reduction (BLVR) or Lung Volume Reduction Surgery (LVRS) can have a significantly positive impact on a patient’s quality of life.
B4 Symptoms, in collaboration with Lahey Hospital and Medical Center, a B4-sponsored pilot site, initiated a comprehensive screening program using 4DMedical’s advanced imaging analysis software, based on Imbio Technology. This program aims to identify patients who could benefit from BLVR and LVRS therapies for advanced emphysema.
